Abstract: The present disclosure provides an automated method of producing genetically modified immune cells, including chimeric antigen receptor T (CAR T) cells, utilizing a fully-enclosed cell engineering system.

Abstract: The present disclosure provides cell culture chambers for use in automated cell engineering systems, and in particular, cell culture chambers that provide increased cell yield. A cell culture chamber may include a first body forming a first portion of the cell culture chamber. A cell culture chamber may include a second body forming a second portion of the cell culture chamber, the first body and the second body configured to couple together, forming an enclosed volume, wherein a first non-porous, gas-permeable material is disposed on the first body; and wherein the first non-porous, gas-permeable material and the first body are formed together. A second non-porous, gas-permeable material may be disposed on the second body, and the second non-porous, gas-permeable material and the second body may be formed together. The cell culture chamber may further include at least one bubble trap integrally formed with the first body and/or the second body.

Abstract: The present disclosure provides an automated method of producing genetically modified immune cells, including chimeric antigen receptor T (CAR T) cells, utilizing a fully-enclosed cell engineering system.

Abstract: The present disclosure provides an automated method of producing genetically modified immune cells, including chimeric antigen receptor T (CAR T) cells, utilizing a fully-enclosed cell engineering system.

Abstract: The present disclosure provides an automated method of producing genetically modified immune cells, including chimeric antigen receptor T (CAR T) cells, utilizing a fully-enclosed cell engineering system.

Abstract: The present disclosure provides an automated method of producing genetically modified immune cells, including chimeric antigen receptor T (CAR T) cells, utilizing a fully-enclosed cell engineering system.

Abstract: Systems and methods for process control of automated cell engineering systems are provided. Automated cell engineering systems provide automated cell processing functionality. Automated process control systems provide control, interconnectivity, monitoring, data archival, software updating, and other oversight functions for automated cell engineering systems. Further, central control process systems provide control, monitoring, data archival, software updating, and other oversight functions for automated process control systems.

Abstract: The present disclosure provides an automated method of producing genetically modified immune cells, including chimeric antigen receptor T (CAR T) cells, utilizing a fully-enclosed cell engineering system.

Abstract: The present disclosure provides an automated method of producing genetically modified immune cells, including chimeric antigen receptor T (CAR T) cells, utilizing a fully-enclosed cell engineering system.

Abstract: The present disclosure provides an automated method of producing genetically modified immune cells, including chimeric antigen receptor T (CAR T) cells, utilizing a fully-enclosed cell engineering system.

Abstract: The present disclosure provides an automated method of producing genetically modified immune cells, including chimeric antigen receptor T (CAR T) cells, utilizing a fully-enclosed cell engineering system.

Abstract: Systems, devices and methods for automatic magnetic separation of magnetized targets in a biological sample are herein disclosed, where they comprise a magnetic field shield/barrier controllably operable to control the magnetic field in terms of reaching and attracting the magnetized targets within the biological sample.

Abstract: The present disclosure provides cell culture chambers for use in automated cell engineering systems, and in particular, cell culture chambers that include improved cell-contacting surfaces. Improved cell-contacting surfaces can include a surface coating that promotes cell growth, adherence, differentiation, maintenance of phenotype, and/or improves transduction; a cell-contacting surface comprising a non-porous, gas-permeable material; as well as other modifications to the cell-contacting surfaces. Cassettes comprising the cell culture chambers are also provided.

Abstract: The present disclosure provides cell therapy production systems that can suitably be used in a patient bedside setting. Such systems allow for direct removal of a patient's blood, automated processing to produce a cell therapy, and then infusion back into the patient, without the need to remove the system from the patient's bedside. Also provided herein are systems for production of cell therapies in a bedside setting.

Abstract: The present disclosure provides an automated method of producing genetically modified immune cells, including chimeric antigen receptor T (CAR T) cells, utilizing a fully-enclosed cell engineering system.

Abstract: The present disclosure provides an automated method of producing genetically modified immune cells, including chimeric antigen receptor T (CAR T) cells, utilizing a fully-enclosed cell engineering system.